Biolexis Therapeutics

Biolexis Therapeutics is a clinical-stage biopharmaceutical company focused on developing small molecule therapeutics for various diseases including cancer, immune-mediated disorders, neurodegenerative conditions, autoimmune diseases, metabolic disorders, and inflammatory diseases. The company utilizes its proprietary AI-enabled drug discovery platform called MolecuLern to rapidly identify and develop novel clinical candidates.

Biolexis' MolecuLern platform leverages empirical wet lab data-driven models trained on the company's curated library of physical and virtual synthesis-ready fragments and novel chemical entities. This process allows Biolexis to identify lead molecules targeting any class of protein, significantly accelerating the drug discovery timeline from years to months. As of November 2023, Biolexis had 40 active programs in discovery and 10 pipeline programs in IND-enabling stages of development using the MolecuLern process.

The company's pipeline includes several promising drug candidates. In October 2023, Biolexis launched a subsidiary called Metabolexis to develop three targeted oral small molecules for obesity and type two diabetes treatment. These include isoform-specific activators of AMPK, aGLP-1/GLP-1R agonists, and mTORC1 inhibitors. Biolexis plans to file Investigational New Drug Applications for all three agents by the end of Q4 2024 and initiate Phase I clinical trials in Q1 2025. The company believes its orally-delivered small molecule therapeutics can address toxicity and delivery complications associated with existing treatments for metabolic disorders.

In addition to its internal pipeline, Biolexis aims to partner with pharmaceutical and biotech companies to accelerate drug development for external parties using its MolecuLern platform. The company's founders, Dr. David J. Bearss and Dr. Hariprasad Vankayalapati, have extensive experience in drug discovery, having filed over 20 Investigational New Drugs and secured more than 100 patents throughout their careers.